BioSpace News Archive

Immunomic Therapeutics, Inc., a privately-held clinical-stage biotechnology company pioneering the study of LAMP -mediated nucleic acid-based immunotherapy announced the appointment of Brian Stamper to Vice President, Cell Therapy Operations.

The latest market analysis report published by Reports and Data, titled ‘Global Ureteral Stents Market – Forecast to 2028,’ thoroughly examines the Ureteral Stents industry to provide essential data & information for the targeted readers. The report consists of quantitative and qualitative research on the market performed by our market experts.

Increasing prevalence of various chronic and acute disorders, rising availability of advanced ambulatory devices, and rapid adoption of ambulatory devices are expected drive global Ambulatory Device market growth.

Increasing applications of pectin in various end-use industries such as pharmaceuticals, cosmetic, and food and beverages, rapid advancement in processing technologies, and rising consciousness of health among individuals are some key factors expected to drive Pectin market revenue growth.

Icahn Mount Sinai and BioMark have agreed to explore multiple areas of collaboration as they share a mutual interest in researching, developing, and commercializing an integrative “multiomics” test for early detection and management of cancer following a successful outcome of this study.

The DMT Study is being conducted in the Netherlands at the Centre for Human Drug Research, a leading independent foundation specializing in innovative early-stage clinical drug research, in 50 healthy volunteers who smoke (cigarettes/nicotine users).

Novartis today announced longer-term follow-up data from the Phase III ASCEMBL trial for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors (TKIs), presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, just one week after receiving IDE approval.

AB Science SA (Euronext - FR0010557264 - AB) today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids (OCS) in the peer-reviewed Journal of Asthma and Allergy.

Tevogen Bio, a late-stage biotechnology company specializing in developing cell and gene therapies in oncology, neurology, and virology, today announced it has initiated the fourth and final dose level of its investigational T cell therapy for high-risk COVID-19 patients.